JP7565132B2 - がんの治療又は予防用医薬 - Google Patents

がんの治療又は予防用医薬 Download PDF

Info

Publication number
JP7565132B2
JP7565132B2 JP2024505170A JP2024505170A JP7565132B2 JP 7565132 B2 JP7565132 B2 JP 7565132B2 JP 2024505170 A JP2024505170 A JP 2024505170A JP 2024505170 A JP2024505170 A JP 2024505170A JP 7565132 B2 JP7565132 B2 JP 7565132B2
Authority
JP
Japan
Prior art keywords
salt
solvate
compound
compound represented
molecular targeted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2024505170A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023204259A1 (https=
JPWO2023204259A5 (https=
Inventor
浩 田中
清明 坂田
雅巳 長谷川
仁志 佐瀬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JPWO2023204259A1 publication Critical patent/JPWO2023204259A1/ja
Publication of JPWO2023204259A5 publication Critical patent/JPWO2023204259A5/ja
Application granted granted Critical
Publication of JP7565132B2 publication Critical patent/JP7565132B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
JP2024505170A 2022-04-20 2023-04-19 がんの治療又は予防用医薬 Active JP7565132B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2022069320 2022-04-20
JP2022069320 2022-04-20
EP22207829.7 2022-11-16
EP22207829 2022-11-16
PCT/JP2023/015683 WO2023204259A1 (ja) 2022-04-20 2023-04-19 がんの治療又は予防用医薬

Publications (3)

Publication Number Publication Date
JPWO2023204259A1 JPWO2023204259A1 (https=) 2023-10-26
JPWO2023204259A5 JPWO2023204259A5 (https=) 2024-04-01
JP7565132B2 true JP7565132B2 (ja) 2024-10-10

Family

ID=88419939

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024505170A Active JP7565132B2 (ja) 2022-04-20 2023-04-19 がんの治療又は予防用医薬

Country Status (6)

Country Link
US (1) US20250262194A1 (https=)
EP (1) EP4512401A4 (https=)
JP (1) JP7565132B2 (https=)
CN (1) CN119031911A (https=)
TW (1) TW202404586A (https=)
WO (1) WO2023204259A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025146040A1 (zh) * 2024-01-01 2025-07-10 华健未来（成都）科技股份有限公司 芳香酰肼类衍生物及其医药用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021149776A1 (ja) 2020-01-22 2021-07-29 中外製薬株式会社 抗腫瘍活性を有するアリールアミド誘導体
WO2022018875A1 (ja) 2020-07-22 2022-01-27 中外製薬株式会社 アリールアミド誘導体を含む細胞増殖性疾患の治療又は予防用医薬組成物
WO2022019329A1 (ja) 2020-07-22 2022-01-27 中外製薬株式会社 アリールアミド誘導体を含む組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20230523T1 (hr) 2013-09-06 2023-08-04 Taiho Pharmaceutical Co., Ltd. Antitumorski agens i sredstvo za poboljšavanje antitumorskog efekta
JP7377679B2 (ja) * 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
JP2021063014A (ja) 2019-10-10 2021-04-22 国立大学法人 東京大学 白血病治療薬
WO2021076655A1 (en) * 2019-10-15 2021-04-22 Amgen Inc. Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers
CN115279376A (zh) * 2020-01-31 2022-11-01 维瑞斯特姆股份有限公司 用于治疗异常细胞生长的组合疗法
BR112023025916A2 (pt) * 2021-06-09 2024-02-27 Chugai Pharmaceutical Co Ltd Combinação de um inibidor de braf e um inibidor de mek, uso de uma combinação, método para o tratamento ou profilaxia de câncer, composições farmacêuticas e invenção

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021149776A1 (ja) 2020-01-22 2021-07-29 中外製薬株式会社 抗腫瘍活性を有するアリールアミド誘導体
WO2022018875A1 (ja) 2020-07-22 2022-01-27 中外製薬株式会社 アリールアミド誘導体を含む細胞増殖性疾患の治療又は予防用医薬組成物
WO2022019329A1 (ja) 2020-07-22 2022-01-27 中外製薬株式会社 アリールアミド誘導体を含む組成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cancer Res，2020年，80 (16_Suppl.)，Abstract CT143
Cancer Sci.，2021年，12(10):4166-4175

Also Published As

Publication number Publication date
CN119031911A (zh) 2024-11-26
JPWO2023204259A1 (https=) 2023-10-26
TW202404586A (zh) 2024-02-01
WO2023204259A1 (ja) 2023-10-26
US20250262194A1 (en) 2025-08-21
EP4512401A4 (en) 2026-01-28
EP4512401A1 (en) 2025-02-26

Similar Documents

Publication Publication Date Title
JP7540104B2 (ja) がんの治療または予防用医薬
KR101950044B1 (ko) Ａｋｔ 억제제 화합물 및 베무라페닙의 조합물, 및 사용 방법
KR20220148847A (ko) 다브라페닙, erk 억제제, 및 shp2 억제제를 포함하는 삼중 약학적 조합물
WO2025067459A2 (en) Therapies for the treatment of cancer
US9682082B2 (en) Combinations of AKT and MEK inhibitor compounds, and methods of use
JP7234418B2 (ja) Ｂｒａｆｖ６００ｅ大腸癌の治療に使用するためのｅｒｋ１／２阻害剤と、ｂｒａｆ阻害剤およびｅｇｆｒ阻害剤との三重組み合わせ
CN118974089A (zh) 基于pd-1抑制剂和sik3抑制剂的组合疗法
JP7565132B2 (ja) がんの治療又は予防用医薬
CN120676939A (zh) Pi3k抑制剂及其制备和使用方法
HK40112852A (zh) 癌的治疗或预防用药物
CA3243264A1 (en) Medicine for treating or preventing cancer
HK40108632A (zh) 癌的治疗或预防用药物
WO2025100519A1 (ja) ジヒドロクロメン誘導体を含むがんの治療剤
EP4504189A1 (en) Methods of treating solid tumor using (19r)-5-chloro-3-ethyl-16-fluoro-10,19-dimethyl-20-oxa-3,4,10,11,23-pentaazapentacyclo[19.3.1.02,6.08,12.013,18]pentacosa-1(24),2(6),4,8,11,13,15,17,21(25),22-decaen-22-amine
KR20220148846A (ko) 다브라페닙, erk 억제제, 및 raf 억제제를 포함하는 삼중 약학적 조합물
US20220378776A1 (en) Drug combination of quinoline derivative and pd-1 monoclonal antibody
BR112019027967A2 (pt) forma b cristalina isolada, composição farmacêutica, método para o tratamento de um distúrbio, método de um composto ou composição, e, processo para produzir forma b cristalina.
BR112019027967B1 (pt) Forma b cristalina isolada, composição farmacêutica, uso de um composto ou composição, e, processo para produzir forma b cristalina
HK1193754A (en) Combinations of akt and mek inhibitor compounds, and methods of use
NZ617243B2 (en) Combinations of akt and mek inhibitor compounds, and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240126

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240126

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20240126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240531

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240924

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240926

R150 Certificate of patent or registration of utility model

Ref document number: 7565132

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150